Surrozen (SRZN) Stock Forecast & Price Target

Surrozen is a clinical-stage biotechnology company that is focused on developing drug candidates to selectively modulate the Wnt pathway, with the potential to provide therapeutic durability and maintained visual and anatomical outcomes for retinal diseases. With promising preclinical results and the upcoming presentation of research for SZN-8141 at a major conference, Surrozen is well-positioned to potentially enter the clinic with a strong foothold in the retinal space. However, potential competition and the need for substantial financing are potential risks to consider when evaluating the long-term outlook for this company.

Surrozen is awaiting clinical initiation for SZN-8141 and has seen increased patients seeking novel treatment, driving their valuation to an equally-weighted composite of $35.69 per share based on a 20x multiple of taxed and diluted 2036 EPS of $6.91 discounted back to December 2026 at 15%, and an NPV discounted cash flow between 2026-2036 of $37.29 per share, with a discount rate of 13% and growth rate of 1%, which is in-line with the expected P/E multiple and discount rates of a developmental-stage biopharmaceutical company. However, their lead agent, SZN-8141, is unproven and their synergy with tri-functional SZN-8143 is uncertain, leading to potential risks in achieving peak commercial revenue estimates.